<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008578</url>
  </required_header>
  <id_info>
    <org_study_id>14-I-0031</org_study_id>
    <secondary_id>14-I-0031</secondary_id>
    <nct_id>NCT02008578</nct_id>
  </id_info>
  <brief_title>Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)</brief_title>
  <official_title>Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, double-blind, placebo-controlled trial of intravenous
      hyperimmune immunoglobulin (Flu-IVIG) in individuals with influenza A or B is to determine
      the pharmacokinetic (PK) profile of Flu-IVIG and assess whether antibody levels observed
      following Flu-IVIG transfusion are similar to those predicted. This pilot study will inform a
      larger study that will be powered to compare Flu-IVIG with placebo for efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized, double-blind, placebo-controlled trial of intravenous
      hyperimmune immunoglobulin (Flu-IVIG) in individuals with influenza A or B is to determine
      the pharmacokinetic (PK) profile of Flu-IVIG and assess whether antibody levels observed
      following Flu-IVIG transfusion are similar to those predicted. This pilot study will inform a
      larger study that will be powered to compare Flu-IVIG with placebo for efficacy. In addition
      to informing the Flu-IVIG dosing required for the clinical outcomes trial, the pilot study
      will compare influenza antibody levels and safety for study participants randomly assigned
      Flu-IVIG and those assigned placebo, assess the feasibility of enrollment, evaluate
      randomization and blinding procedures, and possibly obtain some preliminary data on efficacy
      that may be used to inform sample size and study procedures for the clinical outcomes study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HAI) titer for each influenza strain (H1N1, H3N2, B) taken 1 hour postinfusion compared to predicted levels.</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare HAI titers in active drug versus placebo recipients at 1 hour post-infusion, and Study Days 1, 3, and 7 according to the strain and subtype of virus with which participants are infected</measure>
    <time_frame>Measured through Day 7</time_frame>
    <description>assessment of influenza viral replication by Day 3; preliminary assessment of possible antiviral efficacy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of hospital stay (for hospitalized participants)</measure>
    <time_frame>Measured through the participant's hospital stay</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported functional status and symptoms on Days 3 and 7</measure>
    <time_frame>Measured through Day 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse effects of the study treatment</measure>
    <time_frame>Measured through Day 28</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Intravenous hyperimmune immunoglobulin (Flu-IVIG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults with confirmed Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive 0.25g Flu-IVIG/kg of actual body weight, to a maximum dose of 25g Flu-IVIG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adults with Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive placebo for Flu-IVIG (a comparable volume of saline).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous hyperimmune immunoglobulin (Flu-IVIG)</intervention_name>
    <arm_group_label>Intravenous hyperimmune immunoglobulin (Flu-IVIG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Signed informed consent

               2. Age greater than or equal to 18 years of age

               3. Outpatients or inpatients who are PCR or rapid Ag positive for influenza A or B
                  preferably within 24 hours and no later than 6 days from symptom onset

               4. Onset of illness no more than 6 days before randomization, defined as when the
                  patient first experienced at least one respiratory symptom, constitutional
                  symptom or fever

               5. For women of child-bearing potential, a negative pregnancy test within one day
                  prior to randomization and a willingness to abstain from sexual intercourse or
                  use at least 1 form of hormonal or barrier contraception through Day 28 of the
                  study

               6. Willingness to have blood and respiratory samples obtained and stored

        EXCLUSION CRITERIA:

          1. If hospitalized, admitted for reasons other than influenza or complications of
             influenza

          2. Women who are pregnant or breast-feeding

          3. Strong clinical evidence (in the judgment of the site investigator) that the etiology
             of illness is primarily bacterial in origin.

          4. Prior treatment with any investigational drug therapy within 30 days prior to
             screening

          5. History of allergic reaction to blood or plasma products (as judged by the
             investigator)

          6. Known IgA deficiency

          7. A pre-existing condition or use of medication that, in the opinion of the
             investigator, may place the individual at a substantially increased risk of thrombosis
             (e.g., cryoglobulinemia, severe refractory hypertriglyceridemia, or clinically
             significant monoclonal gammopathy)

          8. Serum creatinine greater than or equal to 1.5 x ULN or known active kidney disease
             that may affect drug pharmacokinetics (e.g., nephrotic syndrome)

          9. Presence of any pre-existing illness that, in the opinion of the investigator, would
             place the individual at an unreasonably increased risk through participation in this
             study

         10. Patients who, in the judgment of the investigator, will be unlikely to comply with the
             requirements of this protocol

         11. Medical conditions for which receipt of 500mL volume may be dangerous to the patient
             (e.g., decompensated congestive heart failure)

         12. Suspicion that infection is due to an influenza strain or subtype other than
             A(H1N1)pdm09, H3N2, or influenza B (e.g., H5N1, H7N9)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Davey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norman Markowitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Henry Ford Hospital, Detroit, MI 48202</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Public Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2014-I-0031.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Dwyer DE; INSIGHT Influenza Study Group. Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies. Vaccine. 2011 Jul 22;29 Suppl 2:B56-62. doi: 10.1016/j.vaccine.2011.04.105.</citation>
    <PMID>21757105</PMID>
  </reference>
  <reference>
    <citation>Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006 Oct 17;145(8):599-609. Epub 2006 Aug 29.</citation>
    <PMID>16940336</PMID>
  </reference>
  <reference>
    <citation>Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Qui√±ones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, Higuera A, Mondragon E, Cordova-Villalobos JA; INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009 Aug 13;361(7):680-9. doi: 10.1056/NEJMoa0904252. Epub 2009 Jun 29.</citation>
    <PMID>19564631</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiviral</keyword>
  <keyword>Adjunctive Therapy</keyword>
  <keyword>Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

